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CLINICAL SCIENCE
Epithelium-Off Corneal Collagen Cross-linking Versus
Transepithelial Cross-linking for Pediatric Keratoconus
Adriano Magli, MD,* Raimondo Forte, MD,* Achille Tortori, MD,† Luigi Capasso, MD,†
Giovanni Marsico, MD,‡ and Elena Piozzi, MD‡
Purpose: To compare efﬁciency and safety of epithelium-off corneal
cross-linking (CXL) and transepithelial cross-linking (TE-CXL) in
pediatric patients with progressive keratoconus.
Methods: Uncorrected and corrected visual acuity, corneal topog-
raphy and pachymetry (Pentacam; Oculus Pentacam), and in vivo
confocal microscopy (HRT II, Rostock Cornea Module, Heidelberg
Engineering, Heidelberg, Germany) were evaluated at baseline and
at 3, 6, and 12 months.
Results: In the epithelium-off CXL group (19 patients, 23 eyes;
mean age, 14.75 6 2.1 years), a signiﬁcant improvement at month
12 was present for Kmax [21.11 diopters (D), P = 0.01], Kmin
(23.2 D, P = 0.001), mean K (21.47 D, P = 0.01), surface asym-
metry index (20.64 D, P = 0.001), inferior–superior symmetry index
(20.54 D, P = 0.01), index of height asymmetry (22.97, P = 0.03),
and anterior elevation at the thinnest location (22.82 D, P = 0.01)
and at the apex (22.27 D, P = 0.01). Postoperative corneal edema
lasted 3 months in 16 eyes (69.5%) and more than 6 months in 2
eyes (8.7%). In the TE-CXL group (10 patients, 14 eyes; mean age,
15 6 4.2 years), a signiﬁcant improvement at month 12 was pre-
sent for Kmax (21.14 D, P = 0.02), Kmin (22.04 D, P = 0.01),
mean K (21.63 D, P = 0.01), surface asymmetry index (20.86 D,
P = 0.001), inferior–superior symmetry index (20.55 D, P = 0.001),
index of height asymmetry (22.95, P = 0.01), and anterior elevation
at the thinnest location (22.96 D, P = 0.01) and at the apex
(22.19 D, P = 0.01). No postoperative corneal edema after TE-CXL
was observed. Changes at month 12 from baseline were not signif-
icantly different between the 2 groups (P . 0.05). TE-CXE was
signiﬁcantly less painful than epithelium-off CXL.
Conclusions: In pediatric patients with progressive keratoconus,
TE-CXL was less painful, provided similar effectiveness and fewer
complications than epithelium-off CXL at 12-month follow-up.
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Keratoconus is a noninﬂammatory process in which thecorneal architecture deforms in association with biome-
chanical weakening. Pediatric age at the time of diagnosis
represents a negative prognostic factor for keratoconus pro-
gression, with high risk for more rapid progression of the
disease and increased probability of corneal transplant.1 Ribo-
ﬂavin UVA corneal collagen cross-linking (CXL) consists of
irradiation with UVA (360 nm wavelength) after application
of 0.1% riboﬂavin in de-epithelialized corneas and represents
the only approach to progressive keratoconus to delay its
progression and to reduce or eliminate the need for donor
keratoplasty.2–4 CXL initiates photopolymerization of the
corneal collagen, causing additional covalent bonds within
collagen ﬁbrils and the quaternary structure of the collagen
and consequent corneal stiffening while maintaining struc-
tural integrity and corneal transparency and preserving
corneal and ocular anatomical and histological structures.
Long-term clinical studies have shown that CXL with epithe-
lium debridement (traditional CXL, epithelium-off CXL)
slows and in most cases blocks progression of keratoconus,5–8
and in some cases, causes an improvement of refractive and
topographic features.3,9,10 CXL performed by administering
0.1% riboﬂavin220% dextran solution without epithelial
debridement (transepithelial cross-linking, TE-CXL) has
shown an efﬁcacy reported to be similar to that of the
epithelium-off CXL.3,11 To date, no reports on utilization of
TE-CXL in pediatric patients are known. Herein, we com-
pared TE-CXL and epithelium-off CXL for treatment of pro-
gressive keratoconus in pediatric patients.
METHODS
The study was performed in accordance with the ethical
standards described in the 2000 revision of the 1964
Declaration of Helsinki. Institutional Review Board approval
was obtained from the University of Naples Federico II for
this study. We retrospectively reviewed the data of all patients
younger than 18 years (range, 12–18 years) and with a diag-
nosis of keratoconus who underwent epithelium-off CXL and
TE-CXL at the University Federico II and Pellegrini Hospital,
Naples, and at Niguarda Hospital, Milan. Inclusion criteria
were age younger than 18 years, conﬁrmed keratoconus,
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central corneal thickness greater than 400 mm, disease pro-
gression documented by an increase in the maximum cone
apex curvature of at least 1.00 diopter (D), an increase in
central corneal astigmatism of at least 1.00 D over the pre-
vious 6 months, clear cornea at biomicroscopic examination,
absence of reticular dark striae at confocal laser microscopy
in vivo, and subjective loss of vision. Dark striae (also named
Vogt striae) are observed in the posterior stroma and Desce-
met layer in the keratoconic cornea and represent collagen
lamellae under stress.12,13 Patients were examined after 6
months if the progressive pattern was not obvious or was
confused by rigid contact lens wear. Both parents of each
patient signed an informed consent form. Contact lens wear-
ers were instructed to discontinue spherical soft lenses for
a minimum of 4 weeks and soft toric, rigid gas-permeable
and hard lenses for a minimum of 12 weeks before the pre-
operative eye examination. Exclusion criteria were central
corneal opacities, a history of herpetic keratitis, severe dry
eye, concurrent corneal infections, concomitant autoimmune
diseases or any ocular surgery, abnormality in lens or retina
on biomicroscopic examination, and patients too young or not
cooperative enough to perform CXL.
Consecutive patients considered eligible for treatment
between May 2006 and September 2009 underwent epithe-
lium-off CXL, whereas consecutive patients included
between October 2009 and January 2011 underwent TE-CXL.
Epithelium-Off Collagen Cross-linking
Epithelium-off CXL was performed according to the
methodology described by Wollensak et al2 Topical anesthe-
sia was administered and the corneal epithelium removed by
mechanical debridement over the central 9.0 mm. To reduce
the risk for UV exposure of retroirideal eye structures, miosis
was induced with 1.0% pilocarpine 30 minutes before the
procedure. Riboﬂavin (0.1% in 20% dextran solution; Ricrolin;
Sooft, Montegiorgio, Italy) was then administered topically
every 2 minutes for 30 minutes. The cornea was exposed
to UVA 365 nm light (Vega CBM X linker; Costruzione
Strumenti Oftalmici, Florence, Italy) for 30 minutes at an
irradiance of 3.0 mW/cm2. During UVA exposure, riboﬂavin
drops were continued every 2 minutes. Postoperatively, anti-
biotic and corticosteroid drops were administered and a ther-
apeutic soft contact lens (Acuvue) was placed. The contact
lens was removed after epithelial healing, typically 3 to 5
days postoperatively. Antibiotic drops were continued for 1
week, and corticosteroid drops were continued for 2 weeks.
TRANSEPITHELIAL CROSS-LINKING
To perform TE-CXL, corneal imbibition was obtained
with 0.1% riboﬂavin–15% dextran solution supplemented with
Tris–hydroxymethyl aminomethane and sodium EDTA (Ricro-
lin TE; Sooft) by instillation of 2 drops every 5 minutes for
30 minutes. One drop of 1% pilocarpine was administered
30 minutes before treatment. Twenty minutes before UV radia-
tion, the cornea was anesthetized with single-dose anesthetic eye
drops (4% lidocaine), 1 drop every 4 minutes. The periocular
skin was disinfected for 5 minutes with povidone–iodine diluted
to 10.0%. A blepharostat was applied, and a ring-shaped silicone
container was used to improve riboﬂavin penetration. Ricrolin
TE was administered every 5 minutes throughout the treatment,
and slit-lamp examination was performed to conﬁrm that sufﬁ-
cient riboﬂavin was in the stroma. Corneal irradiation with an
UVA source (Vega; Costruzione Strumenti Oftalmici) was
then performed at 3 mW/cm2 for 30 minutes. At the end of
treatment, the eye was treated with oﬂoxacin antibiotic eye
drops, and a therapeutic corneal lens bandage (Acuvue) was
applied for 3 days. After therapeutic lens removal, antibiotic
drops were continued for 1 week.
Preoperative and postoperative examination included
uncorrected visual acuity (UCVA), best-corrected visual
acuity (BCVA), corneal topography and pachymetry (Penta-
cam; Oculus Pentacam), and in vivo confocal microscopy
(HRT II, Rostock Cornea Module, Heidelberg Engineering,
Heidelberg, Germany). Visual acuity was evaluated using
a LogMAR Early Treatment Diabetic Retinopathy Study
chart at 4 m. Glare disability was tested with the brightness
acuity tester (BAT; Marco Ophthalmic, Inc).14,15 Monocular
logarithm of the minimum angle of resolution acuities (high
and low contrast) and contrast sensitivities (measured with
Pelli–Robson contrast sensitivity chart) were evaluated in
the presence and absence of BAT glare source at the brightest
setting (1370 candela/m2). Patients were followed up at
3-month intervals during 12 months. Results at baseline,
month 3, month 6, and month 12 are given. Complications
of treatment, including corneal edema, haze (stromal hyper-
density), re-epithelization delay (in epithelium-off CXL
group), hyperemia, and photophobia, were recorded.
Subjective postoperative pain evaluation was evaluated
by the patients using the Wong–Baker FACES Pain Rating
Scale16—a visual analog scale—and recorded in a standard
table. In this self-report structured questionnaire, the patients
are asked to choose the face that best described the degree of
their pain, ranging from 0 to 5 (0 = no pain; 1 = discomfort; 2 =
light pain; 3 = moderate pain; 4 = intense pain; 5 = unbearable
pain). The pain level should correspond to the pain felt during
the respective day, not only at the moment of evaluation.
Statistical analyses were performed with a commercially
available software package (SPSS version 13.0; SPSS, Inc,
Chicago, IL). All data are reported as mean (SD). Repeated-
measures analysis of variance was used to test intragroup
variations of each evaluated parameter from baseline to month
3, month 6, and month 12. Paired t test was used to check the
intergroup difference for change from baseline of evaluated
parameters at each follow-up visit. The level of statistical
signiﬁcance was set at P , 0.05.
RESULTS
Thirty patients (39 eyes) were included in the study.
Mean age was 15.2 6 1.7 (12–17) years with an overall
male to female ratio of 3:1. Characteristics of patients at
baseline and during 12 months of follow-up are shown in
Table 1.
In the epithelium-off CXL group, 19 patients (14
adolescent boys, 5 adolescent girls; 23 eyes) were included,
with a mean age of 14.75 6 2.1 years. Eight patients (42.1%)
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had worn lenses before treatment (soft lenses in 2 cases, rigid
gas-permeable lenses in 6 cases). After treatment, UCVA,
BCVA, corneal central thickness, and endothelial cell count
remained stable at 12-month visit (P . 0.05), whereas a sig-
niﬁcant improvement at month 12 was present for Kmax
(21.11 D, P = 0.01), Kmin (23.2 D, P = 0.001), mean
K (21.47 D, P = 0.01), surface asymmetry index (20.64
D, P = 0.001), inferior–superior symmetry index (20.54 D,
P = 0.01), index of height asymmetry (22.97, P = 0.03), and
anterior elevation at the thinnest location (22.82 D, P = 0.01)
and at the apex (22.27 D, P = 0.01). No signiﬁcant difference
was found in the posterior elevation at the thinnest location
and at the apex from preoperative value at 1 year posttreat-
ment. A signiﬁcant improvement of Kmin, Kmax, and astig-
matism was present at month 3 and month 6. Transient
postoperative corneal edema with glare disability lasted
3 months in 16 eyes (69.5%) (in the absence of a statistically
signiﬁcant visual loss) and was well managed with topical
preservative-free steroids (ﬂuorometholone drops, tapered
3 times a day for 4–6 weeks). Only in 2 eyes (8.7%) corneal
edema persisted until month 8 despite steroidal treatment.
Haze did not occur, and no re-epithelization delay was
noticed.
In the TE-CXL group 11 patients (8 males, 3 females,
16 eyes) were included, with a mean age 156 2.1 years. Four
patients (36.3%) had worn rigid gas-permeable contact lenses
before treatment. After treatment, UCVA, BCVA, corneal
central thickness, and endothelial cell count remained stable
at 12-month visit (P . 0.05), whereas a signiﬁcant improve-
ment at month 12 was present for Kmax (21.14 D, P = 0.02),
TABLE 1. Visual Acuity, Topographic and Confocal Microscopy Data Before and After Epithelium-Off CXL and TE-CXL in Pediatric
Patients
Epithelium-Off CXL, n = 23 Eyes, 14 M/5 F
BL Month 3 Month 6 Month 12 P
UCVA, logMAR 0.68 6 0.21 0.54 6 0.21 0.66 6 0.31 0.67 6 0.24 0.1
BCVA, logMAR 0.36 6 0.1 0.31 6 0.2 0.33 6 0.2 0.36 6 0.1 0.8
Kmin, D 46.31 6 3.4 42.32 6 4.2*,† 43.11 6 3.6*,† 43.13 6 3.5* 0.001
Kmax, D 50.13 6 4.0 48.83 6 4.0*,† 49.38 6 3.6*,† 49.02 6 4.6* 0.01
Mean K, D 47.11 6 3.5 46.81 6 3.3 46.31 6 3.7 45.64 6 4.3* 0.01
Astigmatism, D 5.26 6 3.4 5.05 6 3.2*,† 5.08 6 2.9*,† 5.21 6 3.3 0.3
CCT, mm 487.2 6 1 5.1 509 6 18.2 491 6 20.1 492 6 22.1 0.5
Endothelial cell count, cells/mm2 3212 6 331.1 3195 6 295.2 3193 6 221.3 3188 6 147.1 0.7
Surface asymmetry index 6.76 6 1.32 6.61 6 1.22 6.39 6 1.41* 6.12 6 1.15* 0.001
Inferior–superior symmetry index, mm2 7.40 6 0.7 7.25 6 0.7 7.21 6 1.2 6.84 6 1.1* 0.01
Anterior elevation, thinnest location, D 30.21 6 15.11 26.12 6 16.22† 25.32 6 15.39† 27.39 6 15.56* 0.01
Anterior elevation, apex, D 20.51 6 16.39 17.39 6 18.21† 16.46 6 17.21† 18.24 6 15.21* 0.01
Posterior elevation at the thinnest location, D 54.11 6 28.74 52.18 6 25.76 52.36 6 27.65 52.10 6 29.39 0.07
Posterior elevation at the apex, D 30.10 6 22.11 30.12 6 25.32 30.15 6 23.29 30.8 6 22.65 0.4
IHA 30.11 6 15.8 31.21 6 11.2 31.25 6 14.3 27.14 6 14.8* 0.03
TE-CXL, n = 16 Eyes, 8 M/3 F
BL Month 3 Month 6 Month 12 P
UCVA, logMAR 0.55 6 0.33 0.46 6 0.32 0.48 6 0.21 0.54 6 0.22 0.3
BCVA, logMAR 0.26 6 0.2 0.15 6 0.1 0.22 6 0.4 0.27 6 0.2 0.5
Kmin, D 45.26 6 2.7 47.12 6 5.3† 47.21 6 3.1† 43.22 6 3.1* 0.01
Kmax, D 49.27 6 4.1 49.21 6 5.0† 49.10 6 5.1† 48.13 6 5.4* 0.02
Mean K, D 47.50 6 4.2 48.65 6 4.1 48.66 6 4.3 45.87 6 4.0* 0.01
Astigmatism, D 5.22 6 4.2 5.14 6 4.4† 5.16 6 5.3† 5.33 6 5.1 0.5
CCT, mm 490.2 6 22.3 490.1 6 22.3 485.1 6 17.1 488.0 6 19.3 0.6
Endothelial cell count, cells/mm2 3241.37 6 330.1 3210.2 6 2 21.12 3131 6 127.2 3168.23 6 223.9 0.5
Surface asymmetry index 7.18 6 1.3 7.03 6 1.2 7.01 6 1.1 6.32 6 1.4* 0.001
Inferior–superior symmetry index, mm2 7.24 6 0.4 7.18 6 0.1 7.16 6 0.2 6.69 6 0.1* 0.001
Anterior elevation, thinnest location, D 29.27 6 15.26 29.26 6 17.31† 29.29 6 16.28† 26.31 6 15.32* 0.01
Anterior elevation, apex, D 19.68 6 15.21 19.56 6 20.11† 19.78 6 15.01† 17.49 6 21.08* 0.02
Posterior elevation at the thinnest location, D 53.36 6 25.32 51.14 6 26.39 51.28 6 23.29 51.42 6 26.87 0.07
Posterior elevation at the apex, D 29.59 6 15.76 29.22 6 26.12 29.27 6 21.32 29.35 6 19.39 0.5
IHA 29.34 6 18.2 29.43 6 12.5 29.54 6 15.9 26.39 6 12.1* 0.01
*Statistically signiﬁcant change from baseline.
†Statistically signiﬁcant difference between the 2 groups for change from baseline.
BL, baseline; CCT, corneal central thickness; F, females; IHA, index of height asymmetry; logMAR, logarithm of the minimum angle of resolution; M, males; P, statistical change
at month 12 compared with baseline.
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Kmin (22.04 D, P = 0.01), mean K (21.63 D, P = 0.01),
surface asymmetry index (20.86 D, P = 0.001), inferior–
superior symmetry index (20.55 D, P = 0.001), index of
height asymmetry (22.95, P = 0.01), and anterior elevation
at the thinnest location (22.96 D, P = 0.01) and at the apex
(22.19 D, P = 0.01). No signiﬁcant difference was found in
the posterior elevation at the thinnest location and at the apex
from preoperative value at 1 year posttreatment. All corneas
remained transparent on slit-lamp examination throughout the
follow-up period, with no signs of haze or glare disability.
Side effects of TE-CXL were transient hyperemia (16 of 16
eyes), foreign body sensation (11 of 16 eyes, 68.7%), and
photophobia (16 of 16 eyes) during the ﬁrst few hours and
days after treatment.
A signiﬁcant difference was present between the
2 groups as concerns change from baseline of Kmin, Kmax,
astigmatism, anterior elevation at the thinnest location and at
the apex, at month 3 and at month 6 (P , 0.05) (Table 1). At
month 12, no signiﬁcant differences as concerns change from
baseline of each of the evaluated parameters were present
between the 2 groups.
Mean postoperative pain was signiﬁcantly higher in the
epithelium-off CXL group than in the TE-CXL group in the
immediate postoperative period on the same day as the surgery
(2.9 6 1.2 vs. 1.2 6 1.1, respectively, P = 0.01) and in the
ﬁrst postoperative day (2.3 6 1.2 vs. 0.9 6 0.7, respectively,
P = 0.01), whereas differences were not signiﬁcant during
following 4 days (P . 0.05). When bilateral CXL was
performed, no difference in pain sensitivity was present
between the 2 eyes in any postoperative evaluation in any
group (P . 0.05). No difference in the pain sensitivity was
present between sexes (P . 0.05).
DISCUSSION
To our knowledge, this is the ﬁrst reported evaluation
of TE-CXL in pediatric patients with progressive keratoco-
nus. TE-CXL was compared with epithelium-off CXL. In
TE-CXL, the enhancers trometamol and ethylenediaminete-
traacetic acid are added to help riboﬂavin penetrate the
corneal stroma through an intact epithelium, thereby avoiding
the need for epithelial debridement. According to our data,
both procedures seemed to halt the progression of keratoco-
nus in all treated eyes over the 12-month follow-up. Accord-
ing to epidemiology ﬁndings, an overall male to female ratio
of 3:1 was found. These results slightly differ from the 2:1
value reported by Rabinowitz17 and the 4:1 value recently
reported by Caporossi et al.8
In both groups, UCVA and BCVA improved although
not signiﬁcantly at month 3 and month 6 while decreased to
baseline values at month 12. Pachymetry and endothelial cells
count tended to remain stable during 12 months of follow-up
while a similar signiﬁcant improvement of topographic indices
was present in both groups at month 12, reﬂecting improved
corneal symmetry because of recentering of the corneal apex,
as suggested in previous studies.18 Combined action of 0.1%
riboﬂavin (photosensitizing agent) and UVA irradiation indu-
ces release of singlet oxygen that photopolymerizes stromal
collagen, reduces the lytic effect of collagenase, and increases
corneal resistance to deformation, counteracting certain major
pathophysiologic mechanisms of keratoconus.2,19–21 Although
TE-CXL in pediatric patients has never been reported, a sig-
niﬁcant and fast functional improvement in younger patients
after Riboﬂavin UVA epithelium-off CXL was shown on
a large cohort of patients with a long-term follow-up,11 and
several studies suggest epithelium-off CXL to represent the
primary choice in young patient with progressive keratoco-
nus.6,7 Only one previous report showed a worsening trend
or at least instability of keratoconus in a minority of patients
(approximately 5%) younger than 18 years who had under-
gone traditional CXL.8
In our series, TE-CXL was shown to be safer than
epithelium-off CXL. In the group treated with epithelium-off
CXL, transient corneal edema with glare disability in the ﬁrst
postoperative 12 weeks was present in 80% of cases (without
a statistically signiﬁcant visual loss) and was managed with
topical steroids. Only in 2 cases corneal edema persisted until
month 8 despite steroidal treatment while haze did not occur.
No re-epithelization delay was noticed. In the TE-CXL group,
corneal edema and glare disability were never observed.
Corneal edema is more frequent after epithelium-off CXL
than after TE-CXL, presumably because of a greater exposure
of corneal endothelium to UV damage after removal of
epithelium.3,11,13 Glare disability is caused by corneal edema
and was found only in the epithelium-off CXL group. None
of our patients had a postoperative infection. However, this
complication after epithelium-off CXL has been described.22
Formation of temporary corneal haze, corneal melting, per-
manent scars, endothelial damage, treatment failure, sterile
inﬁltrates, and herpes reactivation are the other reported
complications of epithelium-off CXL.23–26 Sparing of corneal
epithelium in TE-CXL is likely to provide greater safety than
epithelium-off CXL.
In this study, mean postoperative pain was signiﬁcantly
higher in the epithelium-off CXL group than in the TE-CXL
group on the day of the surgery and on the ﬁrst postoperative
day. No signiﬁcant differences were noted during the following
4 days. Postoperative pain after epithelium-off CXL is because
of the exposure of corneal nerves and release of inﬂammatory
mediators, especially prostaglandins and neuropeptides. Post-
operative pain after epithelium-off CXL has been shown to be
intense, especially in the ﬁrst 3 days, even with an aggressive
pain control regimen.27 TE-CXL allows respecting corneal
nerve ﬁbers, is devoid of endothelial toxicity, and is much less
painful than traditional CXL.28,29 Interestingly, Ghanem et al27
showed that postoperative pain after epithelium-off CXL seems
inversely related to patient’s age. Our results agree with the
degree of postoperative pain rating scale observed by Ghanem
et al27 in patients younger than 20 years. Murphy et al30
showed an inverse correlation between corneal sensitivity
and age in both nondiabetic and diabetic subjects, along with
an increasing variability in the measured threshold. They sug-
gested that the number of functional nerves in the peripheral
sensory nervous system decreases with age, and those remain-
ing become less efﬁcient at transmitting signals to the central
nervous system.
Limitations of the present study are the relatively small
number of treated patients and the follow-up limited to 1 year.
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Keratoconus is a progressive disease that can progress during
several decades. Therefore, a longer follow-up is necessary to
deﬁnitely assess the need for retreatment, the effect on
trophicity, and the biomechanics of both procedures.
In conclusion, TE-CXL provided equivalent effectiveness
and fewer complications than epithelium-off CXL at 1-year
follow-up in pediatric patients with progressive keratoconus.
TE-CXL was shown to be a less painful technique in the ﬁrst
postoperative days. A prospective long-term study on a larger
cohort is planned to assess whether TE-CXL could represent
primary choice for treatment in these cases.
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